Blood Red Cells & Iron · Nov 2026

GLP-1 Receptor Agonists and Incident Iron Deficiency in Type 2 Diabetes Mellitus

By Samat DA, Osaghae O, Singh S et al.

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are increasingly prescribed for type 2 diabetes mellitus (T2DM), but their association with iron deficiency in large real-world cohorts remains poorly characterized. We conducted a retrospective cohort study using the TriNetX US Collaborative Network (2019–2020), identifying adults aged 18-65 with T2DM and no prior iron deficiency anemia (IDA), type 1 or gestational diabetes, tirzepatide exposure, or bariatric surgery. After 1:1 propensity score matching including baseline hemoglobin (n=12,667 per cohort), GLP-1 RA use was associated with higher incidence of IDA (9.6% vs 7.1%; HR 1.25, 95% CI 1.15–1.36; p<0.001), lower median ferritin (99.6 vs 140 ng/mL), higher proportion with ferritin <30 ng/mL (5.9% vs 3.5%; HR 1.56, 95% CI 1.39–1.76; p<0.001) and ferritin <15 ng/mL (3.3% vs 2.1%; HR 1.44, 95% CI 1.23–1.69; p<0.001), and similar parenteral iron use (3.1% vs 3.0%; HR 0.93, 95% CI 0.81–1.07; p=0.33). All-cause mortality was significantly lower in GLP-1 RA users (3.7% vs 5.4%; HR 0.63, 95% CI 0.56–0.70; p<0.001). These findings suggest that GLP-1 RA use is associated with lower iron stores, which may occur despite preserved hemoglobin, and support consideration of iron parameter monitoring in patients receiving these agents.

doi.org/10.1016/j.brci.2026.100155Open accessInterventions

AgingResearch.News